amlodipine has been researched along with Diabetes Mellitus in 34 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 9.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| " The metabolic and renal effects of long-term (8 months) therapy with amlodipine, 5 to 10 mg daily, were studied in 15 hypertensive patients with uncomplicated diabetes mellitus as compared with 15 patients with essential hypertension." | 9.07 | Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. ( Beretta-Piccoli, C; Heinen, G; Pingitore, R; Riesen, W; Zanetti-Elshater, F, 1994) |
| "0001), and a lower incidence of pedal edema and adverse events compared with amlodipine." | 6.80 | Efficacy and safety of perindopril arginine + amlodipine in hypertension. ( Bakris, GL; Elliott, WJ; Feldstein, JD; Whitmore, J, 2015) |
| "Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes." | 6.75 | Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010) |
| "Given that hypertension affects ∼60% of patients with diabetes, effective blood pressure (BP) management is important in this high-risk population." | 6.50 | Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis. ( Bhambri, R; Jeffers, BW; Robbins, J, 2014) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 5.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial is the first cardiovascular outcome trial designed to compare initial use of 2 different fixed-dose antihypertensive regimens, benazepril plus hydrochlorothiazide vs benazepril plus amlodipine, on cardiovascular end points in hypertensive patients at high cardiovascular risk secondary to previous major events or presence of diabetes mellitus (DM)." | 5.13 | The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. ( Bakris, G; Dahlof, B; Hester, A; Jamerson, K; Pitt, B; Shi, V; Staikos-Byrne, L; Velasquez, E; Weber, M, 2008) |
| "Losartan induced a drastic decrease in proteinuria accompanied by a reduction in urinary excretion of TGF-beta in patients with non-diabetic proteinuric renal diseases." | 5.10 | Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. ( Aguirre, R; Andrade, CF; Ara, JM; Arias, M; Bernis, C; Campistol, JM; Galceran, JM; Luño, J; Marín, R; Mora, J; Poveda, R; Praga, M; Prat, MV; Rivera, F, 2003) |
| " The metabolic and renal effects of long-term (8 months) therapy with amlodipine, 5 to 10 mg daily, were studied in 15 hypertensive patients with uncomplicated diabetes mellitus as compared with 15 patients with essential hypertension." | 5.07 | Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. ( Beretta-Piccoli, C; Heinen, G; Pingitore, R; Riesen, W; Zanetti-Elshater, F, 1994) |
| " The medical records of diabetic cats were searched for the keywords 'hypertension', 'blood pressure', 'amlodipine', 'benazepril' and 'telmisartan' to identify cats with SH, which was defined as systemic arterial blood pressure (SABP) ⩾160 mmHg, documented at least twice, over several days." | 4.31 | Concurrent disorders of cats with diabetes mellitus and arterial systolic hypertension. ( Hess, RS; Williams, JG, 2023) |
| "During the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, patients with hypertension who received amlodipine had similar cardiovascular risks as those who received candesartan." | 3.88 | Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. ( Ichihara, C; Kitao, H; Konda, M; Kuwabara, Y; Liu, J; Oba, K; Ueshima, K; Yasuno, S, 2018) |
| "0001), and a lower incidence of pedal edema and adverse events compared with amlodipine." | 2.80 | Efficacy and safety of perindopril arginine + amlodipine in hypertension. ( Bakris, GL; Elliott, WJ; Feldstein, JD; Whitmore, J, 2015) |
| "Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes." | 2.75 | Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010) |
| "chlorthalidone treatment with fasting glucose (P < 0." | 2.75 | Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. ( Arnett, DK; Barzilay, JI; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Irvin, MR; Kabagambe, EK; Lynch, AI; Tiwari, HK, 2010) |
| "New-onset diabetes mellitus was defined from adverse event reports, information about new antidiabetic medication and/or a fasting glucose >or=7." | 2.73 | Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. ( Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M; Störset, O, 2008) |
| "In 404 patients with left ventricular hypertrophy, a significantly larger decrease in left ventricular mass index 3 years after enrollment was observed in candesartan-based (n = 205) than amlodipine-based (n = 199) regimens (-22." | 2.73 | ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. ( Fujimoto, A; Nakao, K; Ogihara, T; Saruta, T, 2008) |
| "In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens." | 2.72 | The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. ( Amerena, J; Balazovjech, I; Brunner, HR; Cassel, G; Herczeg, B; Hua, TA; Julius, S; Kjeldsen, SE; Koylan, N; Laragh, J; Magometschnigg, D; Majahalme, S; Martinez, F; McInnes, GT; Oigman, W; Schork, MA; Seabra Gomes, R; Weber, MA; Zanchetti, A; Zhu, JR, 2006) |
| "Given that hypertension affects ∼60% of patients with diabetes, effective blood pressure (BP) management is important in this high-risk population." | 2.50 | Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis. ( Bhambri, R; Jeffers, BW; Robbins, J, 2014) |
| "Amlodipine therapy was also associated with significant slowing in carotid atherosclerosis, an important surrogate marker for CAD, independent of blood pressure changes." | 2.41 | Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. ( Mason, RP, 2002) |
| "The aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients with Hemodialysis and identify factors associated with these interactions if present." | 1.43 | Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. ( Abu-Ghazaleh, D; Al-Ramahi, R; Bsharat, A; Raddad, AR; Rashed, AO; Shehab, O; Yasin, E, 2016) |
| "In the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, the risk of new-onset diabetes was reported to be 23% lower among patients initiating therapy with valsartan versus amlodipine." | 1.34 | Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. ( Edelsberg, J; Jamerson, K; Khan, ZM; Kjeldsen, SE; Oster, G; Vincze, G; Weycker, D, 2007) |
| "Heart failure was two times more prevalent in obese patients." | 1.34 | [Overweight and obesity in hypertensive Spanish patients. The CORONARIA study]. ( Aguilar Llopis, A; Arístegui Urrestarazu, R; Armada Peláez, B; Cosín Aguilar, J; Hernándiz Martínez, A; Masramón Morell, X; Rodríguez Padial, L; Zamorano Gómez, JL, 2007) |
| "Heart failure was four times more frequent in these patients with renal disease than in other hypertensives." | 1.33 | [Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease]. ( Aguilar-Llopis, A; Arístegui-Urrestarazu, R; Cosín-Aguilar, J; Hernándiz-Martínez, A; Masramón-Morell, X; Rodríguez-Padial, L; Zamorano-Gómez, JL, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 17 (50.00) | 29.6817 |
| 2010's | 14 (41.18) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Gnanenthiran, SR | 1 |
| Webster, R | 1 |
| Silva, A | 1 |
| Maulik, PK | 1 |
| Salam, A | 1 |
| Selak, V | 1 |
| Guggilla, RK | 1 |
| Schutte, AE | 1 |
| Patel, A | 1 |
| Rodgers, A | 1 |
| Williams, JG | 1 |
| Hess, RS | 1 |
| Sethi, BK | 1 |
| Baruah, MP | 1 |
| Kumar, AS | 1 |
| Liu, J | 1 |
| Yasuno, S | 1 |
| Oba, K | 2 |
| Konda, M | 1 |
| Ichihara, C | 1 |
| Kitao, H | 1 |
| Kuwabara, Y | 1 |
| Ueshima, K | 2 |
| Barzilay, JI | 3 |
| Lai, D | 1 |
| Davis, BR | 3 |
| Pressel, S | 1 |
| Previn, HE | 1 |
| Arnett, DK | 2 |
| Cho, EJ | 1 |
| Kim, JH | 2 |
| Sutradhar, S | 2 |
| Yunis, C | 2 |
| Westergaard, M | 1 |
| Jeffers, BW | 1 |
| Bhambri, R | 1 |
| Robbins, J | 1 |
| Elliott, WJ | 1 |
| Whitmore, J | 1 |
| Feldstein, JD | 1 |
| Bakris, GL | 1 |
| Saiz Satjes, M | 1 |
| Martinez-Martin, FJ | 1 |
| Al-Ramahi, R | 1 |
| Raddad, AR | 1 |
| Rashed, AO | 1 |
| Bsharat, A | 1 |
| Abu-Ghazaleh, D | 1 |
| Yasin, E | 1 |
| Shehab, O | 1 |
| Aksnes, TA | 1 |
| Kjeldsen, SE | 3 |
| Rostrup, M | 1 |
| Störset, O | 1 |
| Hua, TA | 2 |
| Julius, S | 2 |
| Ogihara, T | 2 |
| Fujimoto, A | 1 |
| Nakao, K | 2 |
| Saruta, T | 2 |
| Bakris, G | 1 |
| Hester, A | 1 |
| Weber, M | 1 |
| Dahlof, B | 1 |
| Pitt, B | 1 |
| Velasquez, E | 1 |
| Staikos-Byrne, L | 1 |
| Shi, V | 1 |
| Jamerson, K | 2 |
| Nilsson, PM | 1 |
| Chrysant, SG | 1 |
| Lee, J | 1 |
| Melino, M | 1 |
| Karki, S | 1 |
| Heyrman, R | 1 |
| Irvin, MR | 1 |
| Lynch, AI | 1 |
| Kabagambe, EK | 1 |
| Tiwari, HK | 1 |
| Eckfeldt, JH | 1 |
| Boerwinkle, E | 1 |
| Ford, CE | 1 |
| Yamamoto, K | 1 |
| Ozaki, H | 1 |
| Takayasu, K | 1 |
| Akehi, N | 1 |
| Fukui, S | 1 |
| Sakai, A | 1 |
| Kodama, M | 1 |
| Shimonagata, T | 1 |
| Kobayashi, K | 1 |
| Ota, M | 1 |
| Horiguchi, Y | 1 |
| Ebisuno, S | 1 |
| Katsube, Y | 1 |
| Yamazaki, T | 1 |
| Ohtsu, H | 1 |
| Hori, M | 1 |
| Punzi, H | 1 |
| Shojaee, A | 1 |
| Waverczak, WF | 1 |
| Maa, JF | 1 |
| Fujita, H | 1 |
| Fujishima, H | 1 |
| Morii, T | 1 |
| Sakamoto, T | 1 |
| Komatsu, K | 1 |
| Hosoba, M | 1 |
| Narita, T | 1 |
| Takahashi, K | 1 |
| Takahashi, T | 1 |
| Yamada, Y | 1 |
| Zamorano, J | 1 |
| Erdine, S | 1 |
| Pavia, A | 1 |
| Al-Khadra, A | 1 |
| Mason, RP | 1 |
| Praga, M | 1 |
| Andrade, CF | 1 |
| Luño, J | 1 |
| Arias, M | 1 |
| Poveda, R | 1 |
| Mora, J | 1 |
| Prat, MV | 1 |
| Rivera, F | 1 |
| Galceran, JM | 1 |
| Ara, JM | 1 |
| Aguirre, R | 1 |
| Bernis, C | 1 |
| Marín, R | 1 |
| Campistol, JM | 1 |
| Weber, MA | 1 |
| McInnes, GT | 1 |
| Zanchetti, A | 1 |
| Brunner, HR | 1 |
| Laragh, J | 1 |
| Schork, MA | 1 |
| Amerena, J | 1 |
| Balazovjech, I | 1 |
| Cassel, G | 1 |
| Herczeg, B | 1 |
| Koylan, N | 1 |
| Magometschnigg, D | 1 |
| Majahalme, S | 1 |
| Martinez, F | 1 |
| Oigman, W | 1 |
| Seabra Gomes, R | 1 |
| Zhu, JR | 1 |
| Cutler, JA | 1 |
| Pressel, SL | 1 |
| Whelton, PK | 1 |
| Basile, J | 1 |
| Margolis, KL | 1 |
| Ong, ST | 1 |
| Sadler, LS | 1 |
| Summerson, J | 1 |
| Cosín-Aguilar, J | 1 |
| Hernándiz-Martínez, A | 1 |
| Arístegui-Urrestarazu, R | 1 |
| Masramón-Morell, X | 1 |
| Aguilar-Llopis, A | 1 |
| Rodríguez-Padial, L | 1 |
| Zamorano-Gómez, JL | 1 |
| Weycker, D | 1 |
| Edelsberg, J | 1 |
| Vincze, G | 1 |
| Khan, ZM | 1 |
| Oster, G | 1 |
| Varughese, GI | 1 |
| Tahrani, AA | 1 |
| Scarpello, JH | 1 |
| Kearney-Schwartz, A | 1 |
| Virion, JM | 1 |
| Stoltz, JF | 1 |
| Drouin, P | 1 |
| Zannad, F | 1 |
| Cosín Aguilar, J | 1 |
| Hernándiz Martínez, A | 1 |
| Masramón Morell, X | 1 |
| Arístegui Urrestarazu, R | 1 |
| Aguilar Llopis, A | 1 |
| Zamorano Gómez, JL | 1 |
| Armada Peláez, B | 1 |
| Rodríguez Padial, L | 1 |
| Fukui, T | 1 |
| Fukiyama, K | 1 |
| Sato, T | 1 |
| Zanetti-Elshater, F | 1 |
| Pingitore, R | 1 |
| Beretta-Piccoli, C | 1 |
| Riesen, W | 1 |
| Heinen, G | 1 |
| Gu, Y | 1 |
| Chen, J | 1 |
| Yang, H | 1 |
| Zhu, W | 1 |
| Lin, F | 1 |
| Zhu, C | 1 |
| Lin, S | 1 |
| Studney, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice[NCT00407537] | Phase 4 | 1,531 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors [NCT00140985] | Phase 4 | 97 participants (Actual) | Interventional | 2000-02-29 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Caduet | -10.0128 |
| Usual Care | -6.8429 |
(NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mmHG (Least Squares Mean) |
|---|---|
| Caduet | -8.3024 |
| Usual Care | -6.6908 |
(NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Caduet | -18.2409 |
| Usual Care | -12.4903 |
(NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mmHG (Least Squares Mean) |
|---|---|
| Caduet | -15.3088 |
| Usual Care | -12.1619 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.1 |
| Usual Care | 3.7 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.0 |
| Usual Care | 3.7 |
"Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12)." (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.7 |
| Usual Care | 4.9 |
"Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12)." (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.7 |
| Usual Care | 4.9 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 12.5 |
| Usual Care | 16.3 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 12.5 |
| Usual Care | 16.3 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12
| Intervention | percent risk (Least Squares Mean) | |
|---|---|---|
| Month 4 | Month 12 | |
| Caduet | -1.8438 | -1.9693 |
| Usual Care | -0.9678 | -0.9963 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12
| Intervention | percent risk (Least Squares Mean) | |
|---|---|---|
| Month 4 | Month 12 | |
| Caduet | -7.2705 | -7.2374 |
| Usual Care | -2.5155 | -2.5167 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | -37.1024 | -33.2420 | -0.4339 | -15.2270 |
| Usual Care | -4.0368 | -3.4168 | -1.0105 | 3.0398 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | -42.7542 | -38.2765 | -0.2060 | -20.5645 |
| Usual Care | -3.8144 | -2.9628 | -1.1978 | 3.0828 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 12
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | 163.3 | 87.1 | 47.3 | 151.5 |
| Usual Care | 196.6 | 117.3 | 47.1 | 166.4 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 4
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | 156.0 | 80.9 | 47.6 | 143.5 |
| Usual Care | 195.2 | 116.4 | 46.8 | 164.8 |
(NCT00407537)
Timeframe: Month 12
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Caduet | 130.6 | 79.2 |
| Usual Care | 134.3 | 81.1 |
(NCT00407537)
Timeframe: Month 4
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Caduet | 133.5 | 80.7 |
| Usual Care | 134.5 | 81.1 |
Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Increased dose | increased dose of anti-hypertensive medications | increased dose of lipid lowering medications | increase in either medication | increase in both medications | |
| Caduet | 30 | 30 | 0 | 4 | 0 |
| Usual Care | 90 | 88 | 2 | 45 | 0 |
Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Month 4: anti-hypertensive and/or lipid lowering | Month 4: anti-hypertensive | Month 4: lipid lowering | Month 4: anti-hypertensive and lipid lowering | Month 12: anti-hypertensive and/or lipid lowering | Month 12: anti-hypertensive | Month 12: lipid lowering | Month 12: anti-hypertensive and lipid lowering | |
| Caduet | 648 | 647 | 45 | 44 | 655 | 654 | 46 | 45 |
| Usual Care | 642 | 637 | 202 | 197 | 642 | 638 | 208 | 204 |
Goals set at <140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and <140/90 mm Hg or <130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| JNC Month 4 | JNC Month 12 | ESC Month 4 | ESC Month 12 | |
| Caduet | 65.2 | 76.1 | 48.6 | 58.2 |
| Usual Care | 62.6 | 60.6 | 46.0 | 47.5 |
Goal set at <100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at <80 mg/dL according to the European (EU) Society of Cardiology guidelines. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| US Month 4 | US Month 12 | EU Month 4 | EU Month 12 | |
| Caduet | 77.3 | 71.9 | 52.4 | 46.7 |
| Usual Care | 28.2 | 28.8 | 13.3 | 11.5 |
6 reviews available for amlodipine and Diabetes Mellitus
| Article | Year |
|---|---|
Blood Pressure Variability in Patients with Diabetes Mellitus with Hypertension: Treatment Recommendations and Role of Amlodipine.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus; Hum | 2017 |
Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Comorbid | 2014 |
Treatment of hypertensive patients with diabetes: beyond blood pressure control and focus on manidipine.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus; Di | 2016 |
Hypertension and diabetes: should we treat early surrogates? What are the cons?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseas | 2009 |
Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Diabetes Complications; Diabetes Mellitus; E | 2002 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
17 trials available for amlodipine and Diabetes Mellitus
| Article | Year |
|---|---|
Reduced efficacy of blood pressure lowering drugs in the presence of diabetes mellitus-results from the TRIUMPH randomised controlled trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diabetes Mellitus; Drug Combina | 2023 |
The Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive Medications for Incident Glucose-level Elevation.
Topics: Alkadienes; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Calcium Channel Blo | 2019 |
Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asia; Calcium Channel Blockers; Cardiovascular Diseases; | 2014 |
Efficacy and safety of perindopril arginine + amlodipine in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combinati | 2015 |
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood P | 2008 |
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2008 |
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Glucose; Blood Press | 2008 |
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bla | 2010 |
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2010 |
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte | 2011 |
Proactive cardiovascular risk management versus usual care in patients with and without diabetes mellitus: CRUCIAL trial subanalysis.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Drug Combination | 2012 |
Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.
Topics: Adult; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blocke | 2003 |
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2006 |
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHA
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2006 |
Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Flow Velocity; | 2007 |
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2008 |
Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine.
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabe | 1994 |
11 other studies available for amlodipine and Diabetes Mellitus
| Article | Year |
|---|---|
Concurrent disorders of cats with diabetes mellitus and arterial systolic hypertension.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Cat Diseases; Cats; Diabetes Mellitus; Hy | 2023 |
Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardi | 2018 |
Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Arabs; Aspirin; Calcium Carbonate; Comorbidity; Diabetes | 2016 |
Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2011 |
Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.
Topics: Acetophenones; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents | 2012 |
[Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease].
Topics: Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Coronary Di | 2006 |
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Databases, Factual; Diabetes Mellitus; Diabetes Me | 2007 |
Blood pressure drugs can boost blood sugar. Depending on the drug, though, it may not matter.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Chlorthalidone; Clinical Trials as Topic; Diabet | 2007 |
The putative link between glycemic control and cardiac arrhythmias.
Topics: Amlodipine; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Glucose; Chlorthalidone; Diabetes M | 2007 |
[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study].
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers | 2007 |
[The effects of endothelin blockade on renal expression of angiotensin II type 1 receptor in diabetic hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Bosentan; Cilazapril; Diabetes Complications; Diabetes | 2002 |